Check-Cap (NASDAQ:CHEK) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report sent to investors on Tuesday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of CHEK stock opened at $2.19 on Tuesday. The firm has a market cap of $12.81 million, a P/E ratio of -0.73 and a beta of 0.44. Check-Cap has a 1-year low of $1.78 and a 1-year high of $4.63. The firm’s 50-day simple moving average is $2.24 and its 200-day simple moving average is $2.24.

Check-Cap (NASDAQ:CHEK) last posted its earnings results on Wednesday, May 15th. The medical research company reported ($0.62) earnings per share (EPS) for the quarter. Analysts expect that Check-Cap will post -0.68 earnings per share for the current fiscal year.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.